2016 has been a revolutionary year for companies and consumers in the medical marijuana industry. As the 2016 elections resulted in decriminalization and full legalization of recreational marijuana in multiple states, including Maine and California, opportunities for companies such as AXIM Biotechnologies, Inc. have expanded dramatically. Relaxed regulations open up new consumer markets that AXIM is uniquely poised to serve. With a product pipeline, as innovative as it is expansive, AXIM has plenty to offer the consumers. The company has garnered significant media attention through its focus on developing unique delivery systems for cannabinoid products, such as CBG toothpaste and other oral care products, functional chewing gums, both cosmetic and pharmaceutical skin care products containing unique cannabinoids, gastro-intestinal disease’ products and glaucoma and dry eye products based on cannabinoids.
The most significant aspect of AXIM‘s success in 2016 is how it sets the company up for explosive growth in 2017. By 2018, AXIM is expected to obtain full FDA/EMA registration for one of its innovative cannabinoid products. With new delivery methods and powerful formulations that address symptoms and conditions in a unique way, AXIM‘s product pipeline is changing the pharmaceutical industry. New funding sources have bolstered the clinical trial process for a variety of products that hold the potential for significant earnings when they reach the market.
The AXIM Product Pipeline
AXIM recently published a product pipeline chart that provides a timeline for all stages from pre-clinical trials to the new drug application (NDA) stage. With a variety of protected cannabinoid-based products in production and many more in planning, this chart will help the company’s followers keep track of its rapid progress and new developments. The chart identifies each product and its corresponding trial stage as well as treatment indications and expected NDA dates. Consumers can also see the anticipated date on which each product will arrive on the market. These cannabinoid products are building momentum as researchers uncover new treatment indications that offer relief for patients without many of the side effects that often accompany traditional treatment options. A variety of non-psychoactive products offers relief without the “high” that is typically associated with medical marijuana products. These products also have the benefit of being non-addictive, making them a viable alternative to many traditional analgesics, such as opioids and NSAID’.
AXIM‘s Chief Executive Officer George Anastassov, MD, DDS, MBA, explains that the company is “continuing to develop cannabinoid-based drugs to find answers for health conditions with currently no known sustainable answers.” Anastassov also explains that potential AXIM patients and investors will now easily be able to keep track of its new products through the newly released chart. All products in development by AXIM are scientifically formulated to provide optimal benefits from natural and synthetic cannabinoids and other substances. AXIM‘s current product pipeline of cannabinoid-based products includes MedChew Rx, RENECANN, ORAXIMAX, Suppocann, Cannbleph, Ophthocann, etc.
MedChew Rx is a cannabinoid-based product with a controlled-release formulation and a chewing gum delivery system. This product was formulated to provide relief for multiple sclerosis symptoms such as muscle spasticity and pain. Patients who have difficulty metabolizing oral-delivery treatments may benefit from a dose of MedChew Rx within 30 minutes. RENECANN is the first cannabigerol-based skincare product in the world, providing relief for patients with symptoms of psoriasis, eczema and other skin conditions. ORAXIMAX is the first cannabigerol oral care product line, making it a revolutionary addition to the dental hygiene market. Suppocann is designed to treat painful GI conditions such as Chron’s disease, IBS and IBD. Ophthocann and Cannbleph are both cannabinoid-based products that provide relief for eye conditions such as intraocular pressure and conjunctivitis.
As a world leader in cannabinoid-based product research and development, AXIM‘s clinical trials offer significant opportunities for investors and consumers alike. With the new 2016 financing in place, AXIM will be able to develop even more new and innovative delivery systems for cannabinoid-based products that provide relief for a variety of conditions that do not yet have viable treatment options. Current clinical research focuses on the effectiveness of AXIM‘s products in the treatment of conditions such as Alzheimer’s disease and dementia, Parkinson’s disease, spasticity, chronic pain, multiple sclerosis, psychosis, adult ADHD, and post-traumatic stress disorder. AXIM is also researching treatment options for autism, restless leg syndrome, IBS, IBD, Chron’s disease, psoriasis and other skin conditions. The versatility of cannabinoid-based products allows for the creation of products that are tailored to each condition.
AXIM Biotech recently began pharmacokinetic/pharmacodynamic (PK/PD) studies focused on CanChew Plus Gum. This is the world’s first CBD-based functional chewing gum intended to treat IBS symptoms. Wageningen University in the Netherlands has been conducting PK/PD studies using multiple doses and concentrations of CanChew Plus gum to test their effectiveness, and Phase II trials are expected to proceed on schedule if the concept is proven by the outcome of this studies. It is estimated that these trials will continue for a period of 12 months before full FDA/EMA application for registration.
Recent Funding and the Future of AXIM
2016 marks a major milestone in AXIM‘s growth timeline after the company secured significant private funding to test and develop its products. This funding will allow AXIM to continue its pharmaceutical clinical trials program and move forward with research and development for its cannabinoid-based product pipeline. A series of financial successes in 2016 sets the company up for an even more promising 2017. The anticipated economic impact of MedChew Rx alone may be $4.8 billion. 2016’s funding will allow for expanded clinical trials and a broader market reach. As clinical trials continue to yield support for AXIM‘s products in various treatment indications, there will be even more opportunity to market these life-changing formulations to patients in distress around the world.
About the Author
Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit https://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/